|
1
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Luchtenborg M, Riaz SP, Lim E, Page R,
Baldwin DR, Jakobsen E, Vedsted P, Lind M, Peake MD, Mellemgaard A,
et al: Survival of patients with small cell lung cancer undergoing
lung resection in England, 1998–2009. Thorax. 69:269–273. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sabari JK, Lok BH, Laird JH, Poirier JT
and Rudin CM: Unravelling the biology of SCLC: Implications for
therapy. Nat Rev Clin Oncol. 14:549–561. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nicholson AG, Chansky K, Crowley J,
Beyruti R, Kubota K, Turrisi A, Eberhardt WE, van Meerbeeck J and
Rami-Porta R: Staging and Prognostic Factors Committee, Advisory
Boards, and Participating Institutions; Staging and Prognostic
Factors Committee Advisory Boards and Participating Institutions:
The international association for the study of lung cancer lung
cancer staging project: Proposals for the revision of the clinical
and pathologic staging of small cell lung cancer in the forthcoming
eighth edition of the TNM classification for lung cancer. J Thorac
Oncol. 11:300–311. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
George J, Lim JS, Jang SJ, Cun Y, Ozretić
L, Kong G, Leenders F, Lu X, Fernández-Cuesta L, Bosco G, Müller C,
et al: Comprehensive genomic profiles of small cell lung cancer.
Nature. 524:47–53. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mori N, Yokota J, Akiyama T, Sameshima Y,
Okamoto A, Mizoguchi H, Toyoshima K, Sugimura T and Terada M:
Variable mutations of the RB gene in small-cell lung carcinoma.
Oncogene. 5:1713–1717. 1990.PubMed/NCBI
|
|
8
|
Rudin CM, Durinck S, Stawiski EW, Poirier
JT, Modrusan Z, Shames DS, Bergbower EA, Guan Y, Shin J, Guillory
J, et al: Comprehensive genomic analysis identifies SOX2 as a
frequently amplified gene in small-cell lung cancer. Nat Genet.
44:1111–1116. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Brambilla E, Negoescu A, Gazzeri S,
Lantuejoul S, Moro D, Brambilla C and Coll JL: Apoptosis-related
factors p53, Bcl2, and Bax in neuroendocrine lung tumors. Am J
Pathol. 149:1941–1952. 1996.PubMed/NCBI
|
|
10
|
Arriola E, Canadas I, Arumi M, Rojo F,
Rovira A and Albanell J: Genetic changes in small cell lung
carcinoma. Clin Transl Oncol. 10:189–197. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
de Bono J, Ramanathan RK, Mina L, Chugh R,
Glaspy J, Rafii S, Kaye S, Sachdev J, Heymach J, Smith DC, et al:
Phase I, Dose-escalation, Two-Part trial of the PARP inhibitor
talazoparib in patients with advanced germline BRCA1/2 mutations
and selected sporadic cancers. Cancer Discov. 7:620–629. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Byers LA, Wang J, Nilsson MB, Fujimoto J,
Saintigny P, Yordy J, Giri U, Peyton M, Fan YH, Diao L, et al:
Proteomic profiling identifies dysregulated pathways in small cell
lung cancer and novel therapeutic targets including PARP1. Cancer
Discov. 2:798–811. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Borromeo MD, Savage TK, Kollipara RK, He
M, Augustyn A, Osborne JK, Girard L, Minna JD, Gazdar AF, Cobb MH
and Johnson JE: ASCL1 and NEUROD1 reveal heterogeneity in pulmonary
neuroendocrine tumors and regulate distinct genetic programs. Cell
Rep. 16:1259–1272. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gardner EE, Lok BH, Schneeberger VE,
Desmeules P, Miles LA, Arnold PK, Ni A, Khodos I, de Stanchina E,
Nguyen T, et al: Chemosensitive relapse in small cell lung cancer
proceeds through an EZH2-SLFN11 Axis. Cancer Cell. 31:286–299.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hirai H, Iwasawa Y, Okada M, Arai T,
Nishibata T, Kobayashi M, Kimura T, Kaneko N, Ohtani J, Yamanaka K,
et al: Small-molecule inhibition of Wee1 kinase by MK-1775
selectively sensitizes p53-deficient tumor cells to DNA-damaging
agents. Mol Cancer Ther. 8:2992–3000. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Albertson DG and Pinkel D: Genomic
microarrays in human genetic disease and cancer. Hum Mol Genet.
12:R145–R152. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Singhal S, Miller D, Ramalingam S and Sun
SY: Gene expression profiling of non-small cell lung cancer. Lung
Cancer. 60:313–324. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Al Zeyadi M, Dimova I, Ranchich V, Rukova
B, Nesheva D, Hamude Z, Georgiev S, Petrov D and Toncheva D: Whole
genome microarray analysis in non-small cell lung cancer.
Biotechnol Biotechnol Equip. 29:111–118. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kikuchi T, Daigo Y, Katagiri T, Tsunoda T,
Okada K, Kakiuchi S, Zembutsu H, Furukawa Y, Kawamura M, Kobayashi
K, et al: Expression profiles of non-small cell lung cancers on
cDNA microarrays: Identification of genes for prediction of
lymph-node metastasis and sensitivity to anti-cancer drugs.
Oncogene. 22:2192–2205. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yanaihara N, Caplen N, Bowman E, Seike M,
Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, et
al: Unique microRNA molecular profiles in lung cancer diagnosis and
prognosis. Cancer Cell. 9:189–198. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bhattacharjee A, Richards WG, Staunton J,
Li C, Monti S, Vasa P, Ladd C, Beheshti J, Bueno R, Gillette M, et
al: Classification of human lung carcinomas by mRNA expression
profiling reveals distinct adenocarcinoma subclasses. Proc Natl
Acad Sci USA. 98:13790–13795. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Edgar R, Domrachev M and Lash AE: Gene
expression omnibus: NCBI gene expression and hybridization array
data repository. Nucleic Acids Res. 30:207–210. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rohrbeck A, Neukirchen J, Rosskopf M,
Pardillos GG, Geddert H, Schwalen A, Gabbert HE, von Haeseler A,
Pitschke G, Schott M, et al: Gene expression profiling for
molecular distinction and characterization of laser captured
primary lung cancers. J Transl Med. 6:692008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Takeuchi T, Tomida S, Yatabe Y, Kosaka T,
Osada H, Yanagisawa K, Mitsudomi T and Takahashi T: Expression
profile-defined classification of lung adenocarcinoma shows close
relationship with underlying major genetic changes and
clinicopathologic behaviors. J Clin Oncol. 24:1679–1688. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Barrett T, Wilhite SE, Ledoux P,
Evangelista C, Kim IF, Tomashevsky M, Marshall KA, Phillippy KH,
Sherman PM, Holko M, et al: NCBI GEO: Archive for functional
genomics data sets-update. Nucleic Acids Res. 41:(Database Issue).
D991–D995. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
da Huang W, Sherman BT and Lempicki RA:
Systematic and integrative analysis of large gene lists using DAVID
bioinformatics resources. Nat Protoc. 4:44–57. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Assenov Y, Ramírez F, Schelhorn SE,
Lengauer T and Albrecht M: Computing topological parameters of
biological networks. Bioinformatics. 24:282–284. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rhodes DR, Kalyana-Sundaram S, Mahavisno
V, Varambally R, Yu J, Briggs BB, Barrette TR, Anstet MJ,
Kincead-Beal C, Kulkarni P, et al: Oncomine 3.0: Genes, pathways,
and networks in a collection of 18,000 cancer gene expression
profiles. Neoplasia. 9:166–180. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Garber ME, Troyanskaya OG, Schluens K,
Petersen S, Thaesler Z, Pacyna-Gengelbach M, van de Rijn M, Rosen
GD, Perou CM, Whyte RI, et al: Diversity of gene expression in
adenocarcinoma of the lung. Proc Natl Acad Sci USA. 98:13784–13789.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Diez D, Wheelock AM, Goto S, Haeggström
JZ, Paulsson-Berne G, Hansson GK, Hedin U, Gabrielsen A and
Wheelock CE: The use of network analyses for elucidating mechanisms
in cardiovascular disease. Mol Biosyst. 6:289–304. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Karachaliou N, Pilotto S, Lazzari C, Bria
E, de Marinis F and Rosell R: Cellular and molecular biology of
small cell lung cancer: An overview. Transl Lung Cancer Res.
5:2–15. 2016.PubMed/NCBI
|
|
32
|
Pietanza MC, Byers LA, Minna JD and Rudin
CM: Small cell lung cancer: Will recent progress lead to improved
outcomes? Clin Cancer Res. 21:2244–2255. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sica A and Bronte V: Altered macrophage
differentiation and immune dysfunction in tumor development. J Clin
Invest. 117:1155–1166. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mantovani A, Allavena P, Sica A and
Balkwill F: Cancer-related inflammation. Nature. 454:436–444. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Reiche EM, Nunes SO and Morimoto HK:
Stress, depression, the immune system, and cancer. Lancet Oncol.
5:617–625. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Liu Y, Jiang P, Capkova K, Xue D, Ye L,
Sinha SC, Mackman N, Janda KD and Liu C: Tissue factor-activated
coagulation cascade in the tumor microenvironment is critical for
tumor progression and an effective target for therapy. Cancer Res.
71:6492–6502. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Im JH, Fu W, Wang H, Bhatia SK, Hammer DA,
Kowalska MA and Muschel RJ: Coagulation facilitates tumor cell
spreading in the pulmonary vasculature during early metastatic
colony formation. Cancer Res. 64:8613–8619. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Champoux JJ: DNA topoisomerases:
Structure, function, and mechanism. Annu Rev Biochem. 70:369–413.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chen T, Sun Y, Ji P, Kopetz S and Zhang W:
Topoisomerase IIα in chromosome instability and personalized cancer
therapy. Oncogene. 34:4019–4031. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Jain M, Zhang L, He M, Zhang YQ, Shen M
and Kebebew E: TOP2A is overexpressed and is a therapeutic target
for adrenocortical carcinoma. Endocr Relat Cancer. 20:361–370.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
O'Malley FP, Chia S, Tu D, Shepherd LE,
Levine MN, Bramwell VH, Andrulis IL and Pritchard KI: Topoisomerase
II Alpha and responsiveness of breast cancer to adjuvant
chemotherapy. J Natl Cancer Inst. 101:644–650. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Maga G and Hubscher U: Proliferating cell
nuclear antigen (PCNA): A dancer with many partners. J Cell Sci.
116:3051–3060. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
del Giglio A, O'Brien S, Ford R, Saya H,
Manning J, Keating M, Johnston D, Khetan R, el-Naggar A and
Deisseroth A: Prognostic value of proliferating cell nuclear
antigen expression in chronic lymphoid leukemia. Blood.
79:2717–2720. 1992.PubMed/NCBI
|
|
44
|
Kinugasa S, Tachibana M, Hishikawa Y, Abe
S, Yoshimura H, Monden N, Dhar DK and Nagasue N: Prognostic
significance of proliferating cell nuclear antigen (PCNA) in
squamous cell carcinoma of the esophagus. Jpn J Clin Oncol.
26:405–410. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Caputi M, Esposito V, Groger AM, Pacilio
C, Murabito M, Dekan G, Baldi F, Wolner E and Giordano A:
Prognostic role of proliferating cell nuclear antigen in lung
cancer: An immunohistochemical analysis. In Vivo. 12:85–88.
1998.PubMed/NCBI
|
|
46
|
Oka S, Uramoto H, Shimokawa H, Iwanami T
and Tanaka F: The expression of Ki-67, but not proliferating cell
nuclear antigen, predicts poor disease free survival in patients
with adenocarcinoma of the lung. Anticancer Res. 31:4277–4282.
2011.PubMed/NCBI
|
|
47
|
Zdunek M and Korobowicz E: Expression of
PCNA in non-small cell lung cancer before and after treatment with
cisplatin and vepeside. Pol J Pathol. 51:77–81. 2000.PubMed/NCBI
|
|
48
|
Xiang J, Fang L, Luo Y, Yang Z, Liao Y,
Cui J, Huang M, Yang Z, Huang Y, Fan X, et al: Levels of human
replication factor C4, a clamp loader, correlate with tumor
progression and predict the prognosis for colorectal cancer. J
Transl Med. 12:3202014. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Dai Y and Grant S: New insights into
checkpoint kinase 1 in the DNA damage response signaling network.
Clin Cancer Res. 16:376–383. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Doerr F, George J, Schmitt A, Beleggia F,
Rehkämper T, Hermann S, Walter V, Weber JP, Thomas RK, Wittersheim
M, et al: Targeting a non-oncogene addiction to the ATR/CHK1 axis
for the treatment of small cell lung cancer. Sci Rep. 7:155112017.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Garrett MD and Collins I: Anticancer
therapy with checkpoint inhibitors: What, where and when? Trends
Pharmacol Sci. 32:308–316. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Xie Y, Wei RR, Huang GL, Zhang MY, Yuan YF
and Wang HY: Checkpoint kinase 1 is negatively regulated by miR-497
in hepatocellular carcinoma. Med Oncol. 31:8442014. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Liu B, Qu J, Xu F, Guo Y, Wang Y, Yu H and
Qian B: MiR-195 suppresses non-small cell lung cancer by targeting
CHEK1. Oncotarget. 6:9445–9456. 2015.PubMed/NCBI
|
|
54
|
McNeely S, Beckmann R and Lin Bence AK:
CHEK again: Revisiting the development of CHK1 inhibitors for
cancer therapy. Pharmacol Ther. 142:1–10. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Sen T, Tong P, Stewart CA, Cristea S,
Valliani A, Shames DS, Redwood AB, Fan YH, Li L, Glisson BS, et al:
CHK1 Inhibition in small-cell lung cancer produces Single-agent
activity in Biomarker-defined disease subsets and combination
activity with cisplatin or olaparib. Cancer Res. 77:3870–3884.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Tanaka F, Wada H, Fukui Y and Fukushima M:
Thymidylate synthase (TS) gene expression in primary lung cancer
patients: A large-scale study in Japanese population. Ann Oncol.
22:1791–1797. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Chen CY, Chang YL, Shih JY, Lin JW, Chen
KY, Yang CH, Yu CJ and Yang PC: Thymidylate synthase and
dihydrofolate reductase expression in non-small cell lung
carcinoma: The association with treatment efficacy of pemetrexed.
Lung Cancer. 74:132–138. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Chamizo C, Zazo S, Domine M, Cristóbal I,
García-Foncillas J, Rojo F and Madoz-Gúrpide J: Thymidylate
synthase expression as a predictive biomarker of pemetrexed
sensitivity in advanced non-small cell lung cancer. BMC Pulm Med.
15:1322015. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Ramnath N, Hernandez FJ, Tan DF, Huberman
JA, Natarajan N, Beck AF, Hyland A, Todorov IT, Brooks JS and
Bepler G: MCM2 is an independent predictor of survival in patients
with non-small-cell lung cancer. J Clin Oncol. 19:4259–4266. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Cheung CHY, Hsu CL, Chen KP, Chong ST, Wu
CH, Huang HC and Juan HF: MCM2-regulated functional networks in
lung cancer by multi-dimensional proteomic approach. Sci Rep.
7:133022017. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Ha SA, Shin SM, Namkoong H, Lee H, Cho GW,
Hur SY, Kim TE and Kim JW: Cancer-associated expression of
minichromosome maintenance 3 gene in several human cancers and its
involvement in tumorigenesis. Clin Cancer Res. 10:8386–8395. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Kidokoro T, Tanikawa C, Furukawa Y,
Katagiri T, Nakamura Y and Matsuda K: CDC20, a potential cancer
therapeutic target, is negatively regulated by p53. Oncogene.
27:1562–1571. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Wang L, Zhang J, Wan L, Zhou X, Wang Z and
Wei W: Targeting Cdc20 as a novel cancer therapeutic strategy.
Pharmacol Ther. 151:141–151. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Chang DZ, Ma Y, Ji B, Liu Y, Hwu P,
Abbruzzese JL, Logsdon C and Wang H: Increased CDC20 expression is
associated with pancreatic ductal adenocarcinoma differentiation
and progression. J Hematol Oncol. 5:152012. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Kato T, Daigo Y, Aragaki M, Ishikawa K,
Sato M and Kaji M: Overexpression of CDC20 predicts poor prognosis
in primary non-small cell lung cancer patients. J Surg Oncol.
106:423–430. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Fan C, Chen L, Huang Q, Shen T, Welsh EA,
Teer JK, Cai J, Cress WD and Wu J: Overexpression of major CDKN3
transcripts is associated with poor survival in lung
adenocarcinoma. Br J Cancer. 113:1735–1743. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Yu Y, Jiang X, Schoch BS, Carroll RS,
Black PM and Johnson MD: Aberrant splicing of cyclin-dependent
kinase-associated protein phosphatase KAP increases proliferation
and migration in glioblastoma. Cancer Res. 67:130–138. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Yeh CT, Lu SC, Chen TC, Peng CY and Liaw
YF: Aberrant transcripts of the cyclin-dependent kinase-associated
protein phosphatase in hepatocellular carcinoma. Cancer Res.
60:4697–4700. 2007.
|
|
69
|
Zang X, Chen M, Zhou Y, Xiao G, Xie Y and
Wang X: Identifying CDKN3 gene expression as a prognostic biomarker
in lung adenocarcinoma via Meta-analysis. Cancer Inform. 14 Suppl
2:S183–S191. 2015.
|
|
70
|
Borlado LR and Méndez J: CDC6: From DNA
replication to cell cycle checkpoints and oncogenesis.
Carcinogenesis. 29:237–243. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Sideridou M, Zakopoulou R, Evangelou K,
Liontos M, Kotsinas A, Rampakakis E, Gagos S, Kahata K, Grabusic K,
Gkouskou K, et al: Cdc6 expression represses E-cadherin
transcription and activates adjacent replication origins. J Cell
Biol. 195:1123–1140. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Zhang X, Xiao D, Wang Z, Zou Y, Huang L,
Lin W, Deng Q, Pan H, Zhou J, Liang C and He J: MicroRNA-26a/b
regulate DNA replication licensing, tumorigenesis, and prognosis by
targeting CDC6 in lung cancer. Mol Cancer Res. 12:1535–1546. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Mahadevappa R, Neves H, Yuen SM, Bai Y,
McCrudden CM, Yuen HF, Wen Q, Zhang SD and Kwok HF: The prognostic
significance of Cdc6 and Cdt1 in breast cancer. Sci Rep. 7:9852017.
View Article : Google Scholar : PubMed/NCBI
|
